Oasmia Pharma (OASM) Closes IPO for Gross Proceeds of ~$9.5M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing
October 29, 2015 7:16 AM EDTNEW YORK, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Oasmia Pharmaceutical AB (NASDAQ: OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the "Company"). Oasmia's product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. Oasmia announce the closing of a U.S. underwritten public offering of American Depositary Shares, or ADSs, and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price... More
Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical for the Russian market
October 28, 2015 8:15 AM EDTUPPSALA, Sweden, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Oasmia Pharmaceutical AB ("Oasmia" or the "Company"), a developer of a new generation of drugs within human and veterinary oncology, announced today that it its distribution partner, Pharmasyntez, has executed the first order of Paclical, Oasmia's lead cancer product. Paclical, a novel water-soluble formulation of paclitaxel, was approved in April, 2015 and shipped earlier for commercial sampling purposes. While this announcement will result in the first commercial sales shipment later this quarter, Oasmia expects additional sales announcements.Â
The first order to the Russia market represents an end-user sales value of over $1.5 million. Pharmasyntez, the... More
